Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Retinal Vein Occlusion (BIOS-RVO Study)
The BIOS-RVO study demonstrates that Bevatas is an effective and safe treatment option for both CRVO and BRVO. These findings support the use of Bevatas as a cost-effective alternative to branded anti-VEGF agents, particularly in resource-limited settings.
Authors
- Somnath Chakraborty (ORCID: https://orcid.org/0000-0001-7913-9328)
- Jay Sheth (ORCID: https://orcid.org/0000-0002-3590-7759)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/opth.s473329
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15